Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a...
Clinical Trial
Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)
Notice of allowance of celiprolol method of treatment of vEDS patent application strengthens proprietary position in U.S. until 2038NEWTON, Mass.,...
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and...
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 26, 2022...
HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications
TUCSON, Ariz. and PARIS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science...
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
BOTHELL, Wash., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a...
X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer
A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November...
Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th World Stroke Congress
WILLOWBROOK, Ill., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel...
Hepion Pharmaceuticals Announces Publication of Phase 2a ‘AMBITION’ Clinical Trial Results
- Study met safety, tolerability, and pharmacokinetics primary endpoints - - Reductions in ALT, ProC3, and C6M suggest direct antifibrotic...
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023SAN...
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic EGFR conformations to drive tumor...
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies in solid tumors Employs Candel’s...
Healthcare Triangle Enables Virtual Immersive Experiences and Interactions through Metaverse
Enabling healthcare and life sciences enterprises to implement virtual and augmented environment for patients and clinical trialsPLEASANTON, Calif., Oct. 26,...
Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from...
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory...
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data...
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Poster for presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics enhances understanding of SORT1 expression in...
Dante Genomics creates separate drug discovery and development company Genomic Biopharma Inc.
– Genomic Biopharma Inc. to present abstracts on two drug candidate programs at the 2022 American Society of Human Genetics...